 CNS Pharmaceuticals Inc NASDAQ: CNSP has opened enrollment for its Phase 2 study evaluating its lead candidate, Berubicin, for recurrent Glioblastoma Multiforme GBM. The company intends to enroll approximately 210 subjects. 